Skip to main content
SpringerLink
Log in

Evaluation of Treatment of Locally Recurrent Rectal Cancer

  • Chapter
  • First Online:
Rectal Cancer

Abstract

Locally recurrent rectal cancer is defined as recurrence, progression, or development of new sites of rectal tumor within the pelvis after previous resection for rectal cancer [1]. The rate of local recurrence after primary treatment of rectal cancer with curative intent varies between 2.4 and 10% in modern series [2] and is dependent on a multitude of variables including patient-specific factors, tumor biology, and surgical and oncology practices [3, 4]. Multiple classification systems for local recurrence have been proposed [5–7]. The simplest and most useful system involves categorization into three anatomical groups: central (involving the rectum and/or urogenital organs), posterior (sacral), lateral (pelvic sidewall), or composite (combination of the above) [8]. Of patients who develop a recurrence, 70% will do so within 2 years of surgery and 85% within 3 years [9], although recurrence after more than 6 years has been reported [10].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. The Beyond TME Collaborative. Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes. Br J Surg. 2013;100(8):1009–14.

    Article  Google Scholar 

  2. Rasanen M, Carpelan-Holmstrom M, Mustonen H, Renkonen-Sinisalo L, Lepisto A. Pattern of rectal cancer recurrence after curative surgery. Int J Color Dis. 2015;30(6):775–85.

    Article  Google Scholar 

  3. Bhangu A, Ali SM, Darzi A, Brown G, Tekkis P. Meta-analysis of survival based on resection margin status following surgery for recurrent rectal cancer. Color Dis. 2012;14(12):1457–66.

    Article  CAS  Google Scholar 

  4. Massarweh NN, Hu CY, You YN, et al. Risk-adjusted pathologic margin positivity rate as a quality indicator in rectal cancer surgery. J Clin Oncol. 2014;32(27):2967–74.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Kusters M, Marijnen CA, van de Velde CJ, et al. Patterns of local recurrence in rectal cancer; a study of the Dutch TME trial. Eur J Surg Oncol. 2010;36(5):470–6.

    Article  CAS  PubMed  Google Scholar 

  6. Suzuki K, Dozois RR, Devine RM, et al. Curative reoperations for locally recurrent rectal cancer. Dis Colon Rectum. 1996;39(7):730–6.

    Article  CAS  PubMed  Google Scholar 

  7. Wanebo HJ, Antoniuk P, Koness RJ, et al. Pelvic resection of recurrent rectal cancer: technical considerations and outcomes. Dis Colon Rectum. 1999;42(11):1438–48.

    Article  CAS  PubMed  Google Scholar 

  8. Harji DP, Griffiths B, McArthur DR, Sagar PM. Current UK management of locally recurrent rectal cancer. Color Dis. 2012;14(12):1479–82.

    Article  CAS  Google Scholar 

  9. Kim J. Pelvic exenteration: surgical approaches. Journal of the Korean Society of Coloproctology. 2012;28(6):286–93.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Rodriguez-Bigas MA, Chang GJ, Skibber JM. Multidisciplinary approach to recurrent/unresectable rectal cancer: how to prepare for the extent of resection. Surg Oncol Clin N Am. 2010;19(4):847–59.

    Article  PubMed  Google Scholar 

  11. Mirnezami AH, Sagar PM, Kavanagh D, Witherspoon P, Lee P, Winter D. Clinical algorithms for the surgical management of locally recurrent rectal cancer. Dis Colon Rectum. 2010;53(9):1248–57.

    Article  PubMed  Google Scholar 

  12. You YN, Habiba H, Chang GJ, Rodriguez-bigas MA, Skibber JM. Prognostic value of quality of life and pain in patients with locally recurrent rectal cancer. Ann Surg Oncol. 2011;18(4):989–96.

    Article  PubMed  Google Scholar 

  13. Gagliardi G, Hawley PR, Hershman MJ, Arnott SJ. Prognostic factors in surgery for local recurrence of rectal cancer. Br J Surg. 1995;82(10):1401–5.

    Article  CAS  PubMed  Google Scholar 

  14. Bellomi M, Rizzo S, Travaini LL, et al. Role of multidetector CT and FDG-PET/CT in the diagnosis of local and distant recurrence of resected rectal cancer. Radiol Med. 2007;112(5):681–90.

    Article  CAS  PubMed  Google Scholar 

  15. Kau T, Reinprecht P, Eicher W, Lind P, Starlinger M, Hausegger KA. FDG PET/CT in the detection of recurrent rectal cancer. Int Surg. 2009;94(4):315–24.

    PubMed  Google Scholar 

  16. Selvaggi F, Fucini C, Pellino G, et al. Outcome and prognostic factors of local recurrent rectal cancer: a pooled analysis of 150 patients. Tech Coloproctol. 2015;19(3):135–44.

    Article  CAS  PubMed  Google Scholar 

  17. Rymer B, Curtis NJ, Siddiqui MR, Chand M. FDG PET/CT can assess the response of locally advanced rectal cancer to neoadjuvant chemoradiotherapy: evidence from meta-analysis and systematic review. Clin Nucl Med. 2016;41(5):371–5.

    Article  PubMed  Google Scholar 

  18. Schneider DA, Akhurst TJ, Ngan SY, et al. Relative value of restaging MRI, CT, and FDG-PET scan after preoperative chemoradiation for rectal cancer. Dis Colon Rectum. 2016;59(3):179–86.

    Article  PubMed  Google Scholar 

  19. Watson AJ, Lolohea S, Robertson GM, Frizelle FA. The role of positron emission tomography in the management of recurrent colorectal cancer: a review. Dis Colon Rectum. 2007;50(1):102–14.

    Article  CAS  PubMed  Google Scholar 

  20. Gollub MJ, Cao K, Gultekin DH, et al. Prognostic aspects of DCE-MRI in recurrent rectal cancer. Eur Radiol. 2013;23(12):3336–44.

    Article  CAS  PubMed  Google Scholar 

  21. Lambregts DM, Cappendijk VC, Maas M, Beets GL, Beets-Tan RG. Value of MRI and diffusion-weighted MRI for the diagnosis of locally recurrent rectal cancer. Eur Radiol. 2011;21(6):1250–8.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Kaur H, Choi H, You YN, et al. MR imaging for preoperative evaluation of primary rectal cancer: practical considerations. Radiographics. 2012;32(2):389–409.

    Article  PubMed  Google Scholar 

  23. Chew MH, Brown WE, Masya L, Harrison JD, Myers E, Solomon MJ. Clinical, MRI, and PET-CT criteria used by surgeons to determine suitability for pelvic exenteration surgery for recurrent rectal cancers: a Delphi study. Dis Colon Rectum. 2013;56(6):717–25.

    Article  PubMed  Google Scholar 

  24. Dieguez A. Rectal cancer staging: focus on the prognostic significance of the findings described by high-resolution magnetic resonance imaging. Cancer Imaging. 2013;13(2):277–97.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Sinaei M, Swallow C, Milot L, Moghaddam PA, Smith A, Atri M. Patterns and signal intensity characteristics of pelvic recurrence of rectal cancer at MR imaging. Radiographics. 2013;33(5):E171–87.

    Article  PubMed  Google Scholar 

  26. Park JS, Jang YJ, Choi GS, et al. Accuracy of preoperative MRI in predicting pathology stage in rectal cancers: node-for-node matched histopathology validation of MRI features. Dis Colon Rectum. 2014;57(1):32–8.

    Article  PubMed  Google Scholar 

  27. You YN, Skibber JM, Hu CY, et al. Impact of multimodal therapy in locally recurrent rectal cancer. Br J Surg. 2016;103(6):753–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Esnaola NF, Cantor SB, Johnson ML, et al. Pain and quality of life after treatment in patients with locally recurrent rectal cancer. J Clin Oncol. 2002;20(21):4361–7.

    Article  PubMed  Google Scholar 

  29. Bhangu A, Ali SM, Cunningham D, Brown G, Tekkis P. Comparison of long-term survival outcome of operative vs nonoperative management of recurrent rectal cancer. Color Dis. 2013;15(2):156–63.

    Article  CAS  Google Scholar 

  30. Mylona S, Karagiannis G, Patsoura S, Galani P, Pomoni M, Thanos L. Palliative treatment of rectal carcinoma recurrence using radiofrequency ablation. Cardiovasc Intervent Radiol. 2012;35(4):875–82.

    Article  PubMed  Google Scholar 

  31. Guren MG, Undseth C, Rekstad BL, et al. Reirradiation of locally recurrent rectal cancer: a systematic review. Radiother Oncol. 2014;113(2):151–7.

    Article  PubMed  Google Scholar 

  32. Das P, Delclos ME, Skibber JM, et al. Hyperfractionated accelerated radiotherapy for rectal cancer in patients with prior pelvic irradiation. Int J Radiat Oncol Biol Phys. 2010;77(1):60–5.

    Article  PubMed  Google Scholar 

  33. Yu SK, Bhangu A, Tait DM, Tekkis P, Wotherspoon A, Brown G. Chemoradiotherapy response in recurrent rectal cancer. Cancer Med. 2014;3(1):111–7.

    Article  PubMed  Google Scholar 

  34. Harris CA. Personal communication quoting Solomon, M. at Colorectal Surgical Society of Australia and New Zealand meeting; 2015.

    Google Scholar 

  35. Dozois EJ, Privitera A, Holubar SD, et al. High sacrectomy for locally recurrent rectal cancer: can long-term survival be achieved? J Surg Oncol. 2011;103(2):105–9.

    Article  CAS  PubMed  Google Scholar 

  36. Kido A, Koyama F, Akahane M, et al. Extent and contraindications for sacral amputation in patients with recurrent rectal cancer: a systematic literature review. J Orthop Sci. 2011;16(3):286–90.

    Article  PubMed  Google Scholar 

  37. Brown KG, Solomon MJ, Austin KK, Lee PJ, Stalley P. Posterior high sacral segmental disconnection prior to anterior en bloc exenteration for recurrent rectal cancer. Techniq Coloproctol. 2016;20(6):401–4.

    Article  CAS  Google Scholar 

  38. Shaikh I, Holloway I, Aston W, et al. High subcortical sacrectomy: a novel approach to facilitate complete resection of locally advanced and recurrent rectal cancer with high (S1-S2) sacral extension. Color Dis. 2016;18(4):386–92.

    Article  CAS  Google Scholar 

  39. Uehara K, Ito Z, Yoshino Y, et al. Aggressive surgical treatment with bony pelvic resection for locally recurrent rectal cancer. Eur J Surg Oncol. 2015;41(3):413–20.

    Article  CAS  PubMed  Google Scholar 

  40. Melton GB, Paty PB, Boland PJ, et al. Sacral resection for recurrent rectal cancer: analysis of morbidity and treatment results. Dis Colon Rectum. 2006;49(8):1099–107.

    Article  PubMed  Google Scholar 

  41. Gupta R, Gan TJ. Preoperative nutrition and prehabilitation. Anesthesiol Clin. 2016;34(1):143–53.

    Article  PubMed  Google Scholar 

  42. Pawlik TM, Skibber JM, Rodriguez-Bigas MA. Pelvic exenteration for advanced pelvic malignancies. Ann Surg Oncol. 2006;13(5):612–23.

    Article  PubMed  Google Scholar 

  43. Troja A, El-Sourani N, Abdou A, Antolovic D, Raab HR. Surgical options for locally recurrent rectal cancer--review and update. Int J Color Dis. 2015;30(9):1157–63.

    Article  CAS  Google Scholar 

  44. Quere P, Facy O, Manfredi S, et al. Epidemiology, management, and survival of peritoneal carcinomatosis from colorectal cancer: a population-based study. Dis Colon Rectum. 2015;58(8):743–52.

    Article  CAS  PubMed  Google Scholar 

  45. Brown KG, Koh CE, Solomon MJ, Qasabian R, Robinson D, Dubenec S. Outcomes after en bloc iliac vessel excision and reconstruction during pelvic exenteration. Dis Colon Rectum. 2015;58(9):850–6.

    Article  PubMed  Google Scholar 

  46. Solomon MJ, Brown KG, Koh CE, Lee P, Austin KK, Masya L. Lateral pelvic compartment excision during pelvic exenteration. Br J Surg. 2015;102(13):1710–7.

    Article  CAS  PubMed  Google Scholar 

  47. Shaikh I, Aston W, Hellawell G, et al. Extended lateral pelvic sidewall excision (ELSiE): an approach to optimize complete resection rates in locally advanced or recurrent anorectal cancer involving the pelvic sidewall. Tech Coloproctol. 2015;19(2):119–20.

    Article  CAS  PubMed  Google Scholar 

  48. Solomon MJ, Tan KK, Bromilow RG, Al-mozany N, Lee PJ. Sacrectomy via the abdominal approach during pelvic exenteration. Dis Colon Rectum. 2014;57(2):272–7.

    Article  PubMed  Google Scholar 

  49. Kim TH, Kim DY, Jung KH, et al. The role of omental flap transposition in patients with locoregional recurrent rectal cancer treated with reirradiation. J Surg Oncol. 2010;102(7):789–95.

    Article  PubMed  Google Scholar 

  50. Hyngstrom JR, Tzeng CW, Beddar S, et al. Intraoperative radiation therapy for locally advanced primary and recurrent colorectal cancer: ten-year institutional experience. J Surg Oncol. 2014;109(7):652–8.

    Article  PubMed  Google Scholar 

  51. Wiig JN, Giercksky KE, Tveit KM. Intraoperative radiotherapy for locally advanced or locally recurrent rectal cancer: does it work at all? Acta Oncol. 2014;53(7):865–76.

    Article  CAS  PubMed  Google Scholar 

  52. Klink CD, Binnebosel M, Holy R, Neumann UP, Junge K. Influence of intraoperative radiotherapy (IORT) on perioperative outcome after surgical resection of rectal cancer. World J Surg. 2014;38(4):992–6.

    Article  PubMed  Google Scholar 

  53. Mirnezami R, Chang GJ, Das P, et al. Intraoperative radiotherapy in colorectal cancer: systematic review and meta-analysis of techniques, long-term outcomes, and complications. Surg Oncol. 2013;22(1):22–35.

    Article  PubMed  Google Scholar 

  54. Terezakis S, Morikawa L, Wu A, et al. Long-term survival after high-dose-rate brachytherapy for locally advanced or recurrent colorectal adenocarcinoma. Ann Surg Oncol. 2015;22(7):2168–78.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Tan J, Heriot AG, Mackay J, et al. Prospective single-arm study of intraoperative radiotherapy for locally advanced or recurrent rectal cancer. J Med Imag Radiat Oncol. 2013;57(5):617–25.

    Article  Google Scholar 

  56. Haddock MG, Miller RC, Nelson H, et al. Combined modality therapy including intraoperative electron irradiation for locally recurrent colorectal cancer. Int J Radiat Oncol Biol Phys. 2011;79(1):143–50.

    Article  PubMed  Google Scholar 

  57. Khoo AK, Skibber JM, Nabawi AS, et al. Indications for immediate tissue transfer for soft tissue reconstruction in visceral pelvic surgery. Surgery. 2001;130(3):463–9.

    Article  CAS  PubMed  Google Scholar 

  58. Davidge KM, Raghuram K, Hofer SO, et al. Impact of flap reconstruction on perineal wound complications following ablative surgery for advanced and recurrent rectal cancers. Ann Surg Oncol. 2014;21(6):2068–73.

    Article  PubMed  Google Scholar 

  59. Jensen KK, Rashid L, Pilsgaard B, Moller P, Wille-Jorgensen P. Pelvic floor reconstruction with a biological mesh after extralevator abdominoperineal excision leads to few perineal hernias and acceptable wound complication rates with minor movement limitations: single-centre experience including clinical examination and interview. Color Dis. 2014;16(3):192–7.

    Article  CAS  Google Scholar 

  60. Touny A, Othman H, Maamoon S, Ramzy S, Elmarakby H. Perineal reconstruction using pedicled vertical rectus abdominis myocutaneous flap (VRAM). J Surg Oncol. 2014;110(6):752–7.

    Article  PubMed  Google Scholar 

  61. Campbell CA, Butler CE. Use of adjuvant techniques improves surgical outcomes of complex vertical rectus abdominis myocutaneous flap reconstructions of pelvic cancer defects. Plast Reconstr Surg. 2011;128(2):447–58.

    Article  CAS  PubMed  Google Scholar 

  62. Chong TW, Balch GC, Kehoe SM, Margulis V, Saint-Cyr M. Reconstruction of large perineal and pelvic wounds using gracilis muscle flaps. Ann Surg Oncol. 2015;22(11):3738–44.

    Article  PubMed  Google Scholar 

  63. Boccola MA, Rozen WM, Ek EW, Teh BM, Croxford M, Grinsell D. Inferior gluteal artery myocutaneous island transposition flap reconstruction of irradiated perineal defects. J Plast Reconstr Aesthet Surg. 2010;63(7):1169–75.

    Article  PubMed  Google Scholar 

  64. Pantelides NM, Davies RJ, Fearnhead NS, Malata CM. The gluteal fold flap: a versatile option for perineal reconstruction following anorectal cancer resection. J Plast Reconstr Aesthet Surg. 2013;66(6):812–20.

    Article  CAS  PubMed  Google Scholar 

  65. Wong S, Garvey P, Skibber J, Yu P. Reconstruction of pelvic exenteration defects with anterolateral thigh-vastus lateralis muscle flaps. Plast Reconstr Surg. 2009;124(4):1177–85.

    Article  CAS  PubMed  Google Scholar 

  66. Tashiro J, Yamaguchi S, Ishii T, et al. Salvage total pelvic exenteration with bilateral v-y advancement flap reconstruction for locally recurrent rectal cancer. Case Rep Gastroenterol. 2013;7(1):175–81.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Woods JE, Alter G, Meland B, Podratz K. Experience with vaginal reconstruction utilizing the modified Singapore flap. Plast Reconstr Surg. 1992;90(2):270–4.

    Article  CAS  PubMed  Google Scholar 

  68. Gustafsson UO, Oppelstrup H, Thorell A, Nygren J, Ljungqvist O. Adherence to the ERAS protocol is associated with 5-year survival after colorectal cancer surgery: a retrospective cohort study. World J Surg. 2016;40(7):1741–7.

    Article  PubMed  Google Scholar 

  69. Yang TX, Morris DL, Chua TC. Pelvic exenteration for rectal cancer: a systematic review. Dis Colon Rectum. 2013;56(4):519–31.

    Article  PubMed  Google Scholar 

  70. Harris CA, Solomon MJ, Heriot AG, et al. The outcomes and Patterns of treatment failure after surgery for locally recurrent rectal cancer. Ann Surg. 2015;264(2):323–9.

    Article  Google Scholar 

  71. Alberda WJ, Verhoef C, Schipper ME, et al. The importance of a minimal tumor-free resection margin in locally recurrent rectal cancer. Dis Colon Rectum. 2015;58(7):677–85.

    Article  PubMed  Google Scholar 

  72. Nielsen M, Rasmussen P, Pedersen B, Hagemann-Madsen R, Lindegaard J, Laurberg S. Early and late outcomes of surgery for locally recurrent rectal cancer: a prospective 10-year study in the total mesorectal excision era. Ann Surg Oncol. 2015;22(8):2677–84.

    Article  PubMed  Google Scholar 

  73. Denost Q, Faucheron JL, Lefevre JH, et al. French current management and oncological results of locally recurrent rectal cancer. Eur J Surg Oncol. 2015;41(12):1645–52.

    Article  CAS  PubMed  Google Scholar 

  74. Bedrosian I, Giacco G, Pederson L, et al. Outcome after curative resection for locally recurrent rectal cancer. Dis Colon Rectum. 2006;49(2):175–82.

    Article  PubMed  Google Scholar 

  75. Rombouts AJ, Koh CE, Young JM, et al. Does radiotherapy of the primary rectal cancer affect prognosis after pelvic exenteration for recurrent rectal cancer? Dis Colon Rectum. 2015;58(1):65–73.

    Article  PubMed  Google Scholar 

  76. Hahnloser D, Nelson H, Gunderson LL, et al. Curative potential of multimodality therapy for locally recurrent rectal cancer. Ann Surg. 2003;237(4):502–8.

    PubMed  PubMed Central  Google Scholar 

  77. Colibaseanu DT, Dozois EJ, Mathis KL, et al. Extended sacropelvic resection for locally recurrent rectal cancer: can it be done safely and with good oncologic outcomes? Dis Colon Rectum. 2014;57(1):47–55.

    Article  PubMed  Google Scholar 

  78. Solomon MJ. Re-exenteration for recurrent rectal cancer. Dis Colon Rectum. 2013;56(1):4–5.

    Article  PubMed  Google Scholar 

  79. Harji DP, Sagar PM, Boyle K, Maslekar S, Griffiths B, McArthur DR. Outcome of surgical resection of second-time locally recurrent rectal cancer. Br J Surg. 2013;100(3):403–9.

    Article  CAS  PubMed  Google Scholar 

  80. Thaysen HV, Jess P, Laurberg S. Health-related quality of life after surgery for primary advanced rectal cancer and recurrent rectal cancer: a review. Color Dis. 2012;14(7):797–803.

    Article  CAS  Google Scholar 

  81. Thaysen HV, Jess P, Rasmussen PC, Nielsen MB, Laurberg S. Health-related quality of life after surgery for advanced and recurrent rectal cancer: a nationwide prospective study. Color Dis. 2014;16(7):O223–33.

    Article  CAS  Google Scholar 

  82. Young JM, Badgery-Parker T, Masya LM, et al. Quality of life and other patient-reported outcomes following exenteration for pelvic malignancy. Br J Surg. 2014;101(3):277–87.

    Article  CAS  PubMed  Google Scholar 

  83. Pellino G, Sciaudone G, Candilio G, Selvaggi F. Effect of surgery on health-related quality of life of patients with locally recurrent rectal cancer. Dis Colon Rectum. 2015;58(8):753–61.

    Article  PubMed  Google Scholar 

  84. Miller AR, Cantor SB, Peoples GE, Pearlstone DB, Skibber JM. Quality of life and cost effectiveness analysis of therapy for locally recurrent rectal cancer. Dis Colon Rectum. 2000;43(12):1695–701. discussion 1701–1693

    Article  CAS  PubMed  Google Scholar 

  85. Harji DP, Koh C, Solomon M, Velikova G, Sagar PM, Brown J. Development of a conceptual framework of health-related quality of life in locally recurrent rectal cancer. Color Dis. 2015;17(11):954–64.

    Article  CAS  Google Scholar 

  86. Harji DP, Griffiths B, Velikova G, Sagar PM, Brown J. Systematic review of health-related quality of life issues in locally recurrent rectal cancer. J Surg Oncol. 2015;111(4):431–8.

    Article  PubMed  Google Scholar 

  87. Mannaerts GH, Schijven MP, Hendrikx A, Martijn H, Rutten HJ, Wiggers T. Urologic and sexual morbidity following multimodality treatment for locally advanced primary and locally recurrent rectal cancer. Eur J Surg Oncol. 2001;27(3):265–72.

    Article  CAS  PubMed  Google Scholar 

  88. Zitt M, DeVries A, Thaler J, et al. Long-term surveillance of locally advanced rectal cancer patients with neoadjuvant chemoradiation and aggressive surgical treatment of recurrent disease: a consecutive single-centre experience. Int J Color Dis. 2015;30(12):1705–14.

    Article  Google Scholar 

  89. Dietz DW. Consortium for optimizing surgical treatment of rectal C. Multidisciplinary management of rectal cancer: the OSTRICH. J Gastrointest Surg. 2013;17(10):1863–8.

    Article  PubMed  Google Scholar 

  90. Russell MC, You YN, Hu CY, et al. A novel risk-adjusted nomogram for rectal cancer surgery outcomes. JAMA Surg. 2013;148(8):769–77.

    Article  PubMed  PubMed Central  Google Scholar 

  91. Ling H, Pickard K, Ivan C, et al. The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis. Gut. 2015;65(6):977–89.

    Article  PubMed  PubMed Central  Google Scholar 

  92. Weiser MR, Fichera A, Schrag D, Boughey JC, You YN. Progress in the PROSPECT trial: precision treatment for rectal cancer? Bull Am Coll Surg. 2015;100(4):51–2.

    PubMed  Google Scholar 

  93. Das P, Eng C, Rodriguez-Bigas MA, et al. Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial. Int J Radiat Oncol Biol Phys. 2014;88(2):301–5.

    Article  CAS  PubMed  Google Scholar 

  94. Chung KY, Gore I, Fong L, et al. Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. J Clin Oncol. 2010;28(21):3485–90.

    Article  CAS  PubMed  Google Scholar 

  95. Kopetz S, Desai J, Chan E, et al. Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer. J Clin Oncol. 2015;33(34):4032–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Lee JH, Kim DY, Kim SY, et al. Clinical outcomes of chemoradiotherapy for locally recurrent rectal cancer. Radiat Oncol. 2011;6:51.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Colorectal Unit, Department of Surgery, New Royal Adelaide Hospital North Terrace, Adelaide, SA, 5000, Australia

    Tarik Sammour

  2. Department of Surgical Oncology, MD Anderson Cancer Center, The University of Texas, Austin, TX, 78712, USA

    John M. Skibber

Authors
  1. Tarik Sammour
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John M. Skibber
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John M. Skibber .

Editor information

Editors and Affiliations

  1. Department of Surgical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA

    George J. Chang

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Sammour, T., Skibber, J.M. (2018). Evaluation of Treatment of Locally Recurrent Rectal Cancer. In: Chang, G. (eds) Rectal Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-16384-0_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-16384-0_14

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-16383-3

  • Online ISBN: 978-3-319-16384-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation